Investment Analysts’ Weekly Ratings Updates for Verastem (VSTM)

A number of research firms have changed their ratings and price targets for Verastem (NASDAQ: VSTM):

• 4/11/2026 – Verastem was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/10/2026 – Verastem had its “buy” rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
• 4/10/2026 – Verastem had its “buy” rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
• 3/30/2026 – Verastem had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $15.00 price target on the stock, down from $19.00.
• 3/12/2026 – Verastem is now covered by BTIG Research. They set a “buy” rating and a $19.00 price target on the stock.
• 3/11/2026 – Verastem was upgraded by BTIG Research to “strong-buy”.
• 3/7/2026 – Verastem was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/5/2026 – Verastem had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $19.00 price target on the stock.
• 2/19/2026 – Verastem was given a new $18.00 price target by Mizuho.

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.